Gain Therapeutics Inc
GANX
Market Cap$53M
Close$
$0.43
78.6% downside
Current Fair Value
78.6% downsideOvervalued by 78.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $53.00 Million |
|---|---|
| Enterprise Value | $46.48 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-0.89 |
| Beta | 0.11 |
| Outstanding Shares | 28,685,417 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -2.43 |
|---|---|
| PEG | -18.88 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -2.29 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.44 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Gain Therapeutics Inc
16 employeesGain Therapeutics, Inc. is redefining drug discovery with its See-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options fo...